Proteina Co., Ltd.

Proteina Co., Ltd. develops protein-protein interaction profiling technology. Its technology confirms real-time activation of cancer signal pathways by directly observing the relevant proteins, predicts drug efficacy, and helps doctors choose which inhibitor to prescribe by identifying the bypass signal pathways that cause resistance. The company also offers a single-molecule protein interaction detection platform for analyzing proteins and protein-protein interaction (PPI) information. Proteina Co., Ltd. was founded in 2015 and is based in Seoul, South Korea.